The effect of inhaled glucocorticosteroids in emphysema due to α1 antitrypsin deficiency

Respiratory Medicine

Volumn 91, Issue 5, 1997, Pages 275-279

  Wilcke, J T R ^a   Dirksen, A ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; GLUCOCORTICOID;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY;

EID: 0030928333     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(97)90030-5     Document Type: Article

References (20)

1. Bach K, Sørensen T, Grønlund C et al. Patients with obstructive airways disease in the general population: How can they be found when results from EUROSCOP, ISOLDE and The Copenhagen city lung study appear. Eur Respir J 1995; 8 (Suppl. 19): 167.
2. Yernault JC. Inhaled corticosteroids in COPD: the EUROSCOP study in perspective. Eur Respir J 1992; 5: 1169-1170.
3. Pauwels RA, Löfdahl C-G, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European respiratory society study on chronic obstructive disease (EUROSCOP): Hypothesis and design. Eur Respir J 1992; 5: 1254-1261.
4. Ciba guest symposium. Terminology, definitions and classification of chronic pulmonary emphysema and related conditions. Thorax 1959; 14: 286-299.
5. Fagerhol MK, Cox DW. The Pi polymorphism. Genetic, biochemical and clinical aspects of human alpha-1-antitrypsin. Adv Hum Genet 1981; 11: 1-62.
6. Quanjer P. Standardised lungfunction testing. Bull Eur Physiopathol Respir 1983; 19 (Suppl. 5): 1-95.
7. Dirksen A, Madsen F, Pedersen OF, Vedel AM, Kok-Jensen A. Long term durability and reproducibility of a hand held turbine spirometer. Thorax 1996 (in press).
8. Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994; 88: 165-194.
9. Connolly CK. Diurnal rhythms in airway obstruction. Br J Dis Chest 1979; 73 357-366.
10. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur Respir J 1988; 1: 22-26.
11. Postma DS, Steenhuis EJ, van der Weele T, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985; 67: 56-64.
12. Sahn SA. Corticosteroids in chronic bronchitis and pulmonary emphysema. Chest 1978; 73: 389-396.
13. Weir DC, Gove RI, Robertson AS, Sherwood Burge P. Response to corticosteroids in chronic airflow obstruction: Relationship to emphysema and airway collapse. Eur Respir J 1991; 4: 1185-1190.
14. Beerel FR, Vance JW. Prednisone treatment for stable pulmonary emphysema. Am Rev Respir Dis 1971; 104: 264-266.
15. Blair GP, Light RW. Treatment of chronic obstructive pulmonary disease with corticosteroids: comparison of daily vs alternate day therapy. Chest 1984; 86: 524-528.
16. Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest 1995; 108: 1568-1571.
17. Dirksen A, Christensen H, Evald T et al. Bronchodilator and corticosteroid in reversibility in ambulatory patients with airways obstruction. Danish Med Bull 1991; 38: 486-489.
18. 1-antitrypsin deficiency. Acta Med Scand 1964; 175: 197-205.
19. Dirksen A, Rasmussen FV, Keiding N. Choice of measurement and sample size for detection of changes in lung function in obstructive pulmonary disease. Eur Respir Rev 1991; 1: 432-435.
20. Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.